September 2020 - Sunstone

Cantargias valberedning föreslår ny styrelseledamot

22/09/2020

Cantargias valberedning föreslår ny styrelseledamot Valberedningen i Cantargia AB (publ), som består av Sten Verland (partner i Sunstone Life Science Ventures, ordförande), Jannis Kitsakis (Fjärde AP-fonden), Alexander Mata (Alecta Pensionförsäkring, ömsesidigt) och...

Arimoclomol has been granted FDA Fast Track and Breakthrough Therapy Designations for NPC, as well as Orphan Drug and Rare Pediatric Disease Designations. Orphazyme expects to file an MAA with the EMA for arimoclomol in NPC in H2 2020.

16/09/2020

Arimoclomol has been granted FDA Fast Track and Breakthrough Therapy Designations for NPC, as well as Orphan Drug and Rare Pediatric Disease Designations. Orphazyme expects to file an MAA with the EMA for arimoclomol in NPC in H2 2020. Orphazyme A/S (ORPHA.CO), a...

Are antibody-based therapeutics and venture capital a bad mix?

14/09/2020

Sunstone monitors and analyzes all M&A transactions for therapeutic companies HQ’ed in Europe, with an exit transaction value exceeding EUR 50M. Upon fragmenting the 43 transactions executed between 2010 and 2020 by modalities, we were surprised to observe that...

Are big financing rounds and venture star multiples a realistic expected outcome?

08/09/2020

Like many of our colleagues, our initial investment hypothesis is always to achieve a 5-10x return when we invest. When achieved, these are often referred to as the stars, performers or unicorns of a venture capital portfolio. Sunstone continuously monitors and...

Orphazyme files registration statement in the U.S. in connection with proposed global offering, consisting of initial public offering of ADSs in the U.S. and concurrent private placement of ordinary shares in Europe

07/09/2020

Orphazyme files registration statement in the U.S. in connection with proposed global offering, consisting of initial public offering of ADSs in the U.S. and concurrent private placement of ordinary shares in Europe Orphazyme A/S (ORPHA.CO) (the “Company”), a...

Cantargias valberedning föreslår ny styrelseledamot

Arimoclomol has been granted FDA Fast Track and Breakthrough Therapy Designations for NPC, as well as Orphan Drug and Rare Pediatric Disease Designations. Orphazyme expects to file an MAA with the EMA for arimoclomol in NPC in H2 2020.

Are antibody-based therapeutics and venture capital a bad mix?

Are big financing rounds and venture star multiples a realistic expected outcome?

Orphazyme files registration statement in the U.S. in connection with proposed global offering, consisting of initial public offering of ADSs in the U.S. and concurrent private placement of ordinary shares in Europe

Recent Posts

Recent Comments

Archives

Categories

Meta